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Peak nasal inspiratory flow as outcome 
for provocation studies in allergen exposure 
chambers: a  GA2LEN study
Georg Boelke1* , Uwe Berger2, Karl‑Christian Bergmann1, Carsten Bindslev‑Jensen3, Jean Bousquet4, 
Julia Gildemeister5, Marek Jutel6,7, Oliver Pfaar8,9, Torsten Sehlinger10 and Torsten Zuberbier1
Abstract 
Background: The  GA2LEN chamber has been developed as a novel mobile allergen exposure chamber (AEC) allow‑
ing standardized multicenter trials in allergy. Hitherto, subjective nasal symptom scores have been the most often 
used outcome parameter, but in standardized modern trials objective parameters are preferred. Despite its practica‑
bility, the objective parameter peak nasal inspiratory flow (PNIF) has been rarely used for allergy trials in the setting 
of allergen exposure chambers. This study aims to evaluate PNIF as an outcome parameter for provocation studies in 
AECs.
Methods: In a randomized controlled blinded setting subjects suffering from allergic rhinitis were exposed to grass 
pollen, birch pollen, house dust mite and/or placebo in the  GA2LEN chamber. Different allergen concentrations were 
used to evaluate symptom severities. Patients had to perform PNIF before and every 30 min during a challenge using 
a portable PNIF meter.
Results: 86 subjects participated in 203 challenges, altogether. House dust mite provocations caused the great‑
est reduction in PNIF values, followed by grass pollen and birch pollen. Provocations with every allergen or pollen 
concentration led to a significant decrease (p < 0.05) in PNIF compared to baseline. Furthermore, positive correlations 
were obtained between PNIF and peak expiratory flow, height and weight, and inverse correlations between PNIF and 
total nasal symptom score, nasal congestion score and visual analog scale of overall subjective symptoms.
Conclusion: PNIF is a helpful and feasible tool for conducting provocation trials with allergens, especially grass pol‑
len and house dust mite, in an AEC.
Keywords: Allergen exposure chamber (AEC), Allergy trial, GA2LEN chamber, Peak nasal inspiratory flow (PNIF), 
Provocation study
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Background
Depending on the geographic location and age of the 
patients, allergic rhinitis (AR) affects up to 10–40% of 
world’s population [1–3]. The prevalence of sensitiza-
tion to airborne or indoor allergens reaches even higher 
values [4, 5]. Clinically AR presents especially with nasal 
congestion, sneezing, nasal pruritus and nasal discharge 
[6]. In Europe, major causes for seasonal allergic rhini-
tis are pollen from grass species (e.g. Phleum pratense), 
birch trees (betula) for northern Europe and olive (olea) 
for the Mediterranean regions, respectively, and house 
dust mites (HDM) and animal dander as the most com-
mon reason for perennial allergic rhinitis [7, 8]. AR is 
known to result in a decreased quality of life, sleep disor-
ders, missing days at work or school, decreased produc-
tivity, and eventually causing direct and indirect medical 
costs of billions [9–11]. Hence, there is a great need for 
developing new treatment options and conducting 
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clinical trials in the field of allergy. However, these trials 
are known to be time consuming due to their immanent 
demand on the pollen season. Furthermore, the amount 
of pollen each subject gets exposed to depends on several 
uncontrollable factors like climate, lifestyle and the actual 
pollen load in the air [12]. To overcome these difficulties, 
allergen exposure chambers (AEC) were developed and 
have been used for years in Europe, North America and 
Asia [13]. They provide a controlled, stable and reproduc-
ible environment regardless of the natural pollen season. 
Recently, the  GA2LEN chamber was introduced, a mobile 
exposition chamber using a unique technique of expo-
sure that allows individual allergen exposure for each 
patient during a challenge [14]. Besides subjective scor-
ing through the patient itself during allergen challenges, 
there is a need for objective parameters as well. Out of 
the three most common methods to objectify nasal symp-
toms, namely rhinomanometry, acoustic rhinometry and 
peak nasal inspiratory flow (PNIF), the PNIF has been 
rarely used in the allergen chamber setting. It is cheap, 
portable and provides highly reproducible results despite 
depending on the patients’ cooperation [15]. Moreover, 
it correlates with subjective feeling of nasal obstruction, 
and is both easy and fast to learn [16–18]. PNIF measures 
the total nasal flow, therefore it is not dependent on the 
changing resistances between the left and right nostril 
during the nasal cycle. This study aims to evaluate PNIF 
as an outcome parameter for allergen provocations in an 
AEC. Moreover, associations between PNIF and biomet-
ric data (age, weight, height), PNIF and oral peak expira-
tory flow (PEF), and PNIF and subjective symptom scores 
and visual analog scales (VAS) are investigated.
Methods
Subjects
The study was conducted between January 2015 and May 
2016 in Berlin, Germany. The majority of the trials were 
performed outside and only a few inside of the regional 
pollen season. Included were both male and female sub-
jects between 18 and 75  years old with a history of AR 
caused by grass and/or birch pollen and/or house dust mite 
for at least two years, a positive skin prick test (SPT) (wheal 
diameter ≥3 mm than negative control) for grass mix, birch 
and/or house dust mite (Dermatophagoides pteronyssinus 
and/or Dermatophagoides farinae), and/or ImmunoCAP 
score ≥2 for the allergen they were exposed to. Both smok-
ers and non-smokers were included in this study. Exclusion 
criteria were pregnancy, acute or chronic rhinosinusitis, 
severe asthma, prior immunotherapy, and treatment with 
a nasal decongestant, nasal glucocorticoid, oral antihis-
tamine, oral chromone derivates (up to 7  days prior to 
exposure) or systemic glucocorticoids (up to 30 days prior 
to exposure). Every patient gave written informed consent 
prior to exposure. The study was approved by the ethical 
committee of the Charité (No. EA1/193/14 for grass/birch 
and EA1/152/15 for HDM) and conducted following the 
guidelines from the Declaration of Helsinki.
Methods and material
Subjects were included based on history and skin test 
independent of symptom severity during an exposure. 
The study was planned as modified double-blinded and 
placebo-controlled, patients did neither know if they 
were exposed to an allergen nor the amount of the aller-
gen. Right before each provocation, patients were ran-
domly assigned to a seat using a randomization software. 
Beforehand, particle disperse units above each seat had 
been prepared by a technician uninvolved in the interac-
tions between investigators and patients. The investiga-
tors were sitting in a separated control room exposing 
the patients according to a preset randomized pattern 
only revealed at the start without any interactions dur-
ing the exposure with the patients to ensure a completely 
blinded study. Patients were exposed for 90–240 min for 
grass/birch pollen and 60–90 min for HDM. To get com-
parable results, we focus on data from exposures for at 
least 120  min regarding grass/birch pollen and 90  min 
for HDM. Before the challenge began, patients had to sit 
on their designated seats for at least 15 min to get accli-
mated. Before and every 10  min during the challenge, 
patients had to evaluate their nasal symptoms (itching, 
sneezing, rhinorrhea, congested nose) on a symptom 
check card using a rating scale ranging from zero points 
(no symptoms present) to three points (severest symp-
toms present). All four symptoms were summed up to the 
total nasal symptom score (TNSS) with a highest possible 
score of 12 points. Moreover, before exposure started and 
every 30  min during exposure patients measured their 
PEF using a portable peak flow meter (PFM20, Omron 
Healthcare Europe, Hoofddorp, Netherlands) and their 
PNIF using a portable PNIF meter (In-check, Inspiratory 
flow meter, Clement Clarke International, Essex, UK). 
Before the baseline measurements were conducted, each 
patient was given a short training about how to perform 
the test correctly and to have some trials to avoid a train-
ing effect. Each measurement was taken in a seated posi-
tion, the best of at least two successful measurements was 
noted. PNIF und PEF meter were kept in a closable bag 
next to the patient all throughout the exposure to protect 
them from contamination with allergen and were only 
taken out for the measurements. The patients evaluated 
their overall subjective symptoms being asked to assess 
their present general well-being using a 10 cm (cm) visual 
analog scale (VAS) ranging from very good (0 cm) to very 
bad (10  cm) directly before and every 30  min after the 
start of each challenge. Immediately before and after each 
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challenge participants underwent spirometry for safety. 
Patients could participate multiple times and if eligible 
for each allergen and their different concentrations. For 
this study, only their last visit for each allergen and its dif-
ferent concentrations was included to avoid duplicates.
Allergen exposure chamber
The  GA2LEN chamber consists of two standard 24 ft. 
containers (one for observation and storage, the other 
one for the exposition chamber itself ), the outer dimen-
sions are 7.43 × 5.10 × 2.86 m (length × width × height). 
It can contain up to nine patients per run. Each patient 
gets their individual allergen exposure. Due to strong 
laminar airflow on both sides of the exposition chamber 
and almost no airflow in the area where the subjects are 
seated, there is no mixture of air and the contained aller-
gen between the subjects guaranteeing their individual 
exposure. Detailed information on the technical aspect 
has been published by Zuberbier et  al. [14]. Climate 
conditions were permanently controlled all throughout 
the exposures [temperature was set at 20.5  °C (±0.5 K), 
humidity at 55% (±5%)]. Patients were exposed to 4000 
and 8000  grains/m3 Phleum pratense, 4000, 8000 and 
16,000  grains/m3 Betula pendula (both Allergon AB, 
Ängelholm, Sweden), and 250  µg/m3 house dust mite 
raw material (computed value, consists of whole bod-
ies, body parts and feces; GMP material, equivalent to 
400 ng Der p 1/m3).
Statistics
Data was analyzed and diagrams were created with the 
help of IBM SPSS Statistics Version 24.0 for Windows 
(Armonk, NY: IBM Corp.) and Microsoft Excel 2013 
(Redmond, WA). The challenges were initially performed 
as validation trials for the chamber, thus no specific 
power analysis for differences in PNIF was calculated. 
To compare between the groups, the relative PNIF value 
in percent was computed (PNIF%). Therefore, the sub-
ject’s baseline PNIF was determined as 100%. PNIF% is 
reported as medians with bias corrected and acceler-
ated bootstrap 95% confidence intervals of the median 
(95% BCa CI), absolute PNIF values as mean ± standard 
deviation (SD). A p level of <0.05 was accepted as sig-
nificant. Kruskal–Wallis test and Mann–Whitney-U test 
were used for comparisons between the different treat-
ment groups, Friedman test was used when differences 
in-between a group were examined. Pairwise compari-
sons as post hoc tests were computed using the Dunn–
Bonferroni approach. Spearman rank correlations were 
calculated to assess associations between PNIF and age, 
height, weight, PEF, nasal congestion score, TNSS and 
VAS. For correlations with baseline PNIF, each subject 
was only included once with their best PNIF baseline 
value. For correlations between PNIF and subjective 
symptom scores and VAS, each challenge was included 
using its mean PNIF%, its mean TNSS and nasal con-
gestion score from beginning to end of exposure, and its 
mean VAS during a provocation test minus baseline VAS, 
respectively. Area under the curve (AUC) was calculated 
using the trapezoid rule and is reported as medians and 
95% BCa CI.
Results
86 patients were included, 47 of them were female 
(54.7%). Men had a mean PNIF at baseline of 174.2 (±SD 
59.9 L/min) and women 126.3 (±SD 31.0 L/min). No dif-
ferences were found for PNIF at baseline between in- and 
out-side the pollen season provocations in the chamber. 
Detailed demographics are described in Table 1.
Grass
34 subjects were tested with 4000  grains/m3 of grass 
pollen, 22 subjects with 8000 grains/m3 and 22 subjects 
with placebo. Mean reduction from baseline PNIF was 
32.4 (±SD 20.9 L/min) in the 4000 grains/m3 group, 45.3 
(±SD 23.7 L/min) in the 8000 grains/m3 group and 12.0 
(±SD 14.9 L/min) in the placebo group (Table 2). The rel-
ative PNIF compared to baseline (PNIF%) reduction was 
29.7%, 95% CI (20.1, 32.8) for 4000 grains/m3, 36.8%, 95% 
CI (27.8, 43.8) for 8000 grains/m3 and 8.9%, 95% CI (1.3, 
15.7) for placebo (Additional file  1: Table S1). Kruskal–
Wallis-test found significant differences between the 
PNIF% values of the groups after 30  min (χ2  =  10.357, 
p =  0.006), after 60  min (χ2 =  22.390, p  <  0.001), after 
90  min (χ2  =  26.829, p  <  0.001) and after 120  min 
(χ2 =  20.789, p < 0.001). Post-hoc tests revealed signifi-
cant differences for both 4000 and 8000 grains/m3 com-
pared to placebo at each time of measurement (Fig.  1). 
Furthermore, a significant difference between both active 
Table 1 Patient demographics
FEV1 forced expiratory volume in one second, PNIF peak nasal inspiratory flow, 
PEF peak expiratory flow, SD standard deviation
Parameter (n = 86) Male, n = 39 
(45.3%)
Female, n = 47 
(54.7%)
Age in years, mean (range) 29.3 (19–74) 26.4 (19–47)
Height in m, mean (range) 1.83 (1.72–1.96) 1.69 (1.55–1.80)
Weight in kg, mean (range) 78.5 (54–96) 62.9 (47–88)
Active smokers (%) 6 (15.4%) 4 (8.5%)
Sensitization to grass (%) 32 (82.1%) 39 (83%)
Sensitization to birch (%) 29 (74.4%) 38 (80.9%)
Sensitization to house dust mite (%) 23 (59%) 32 (68.1%)
PNIF in L/min, mean (± SD) 174.2 (±59.9) 126.3 (±31.0)
PEF in L/min, mean (± SD) 588.3 (±83.8) 401.3 (±75.0)
FEV1% predicted, mean (± SD) 92.2 (±11.5) 89.6 (±12.0)
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groups could be detected for PNIF% values at 60  min 
(z = 15.004, p = 0.046). Friedman test showed significant 
differences in each of the both active groups for every 
PNIF% value compared to their baseline, whereas no 
significant difference could be computed in the placebo 
group at all. The AUC for PNIF% was significant lower 
for both active groups [4000  grains/m3 8957.6 (8433.0, 
10,046.6); 8000  grains/m3 8241.7 (7278.1, 9055.6)] 
Table 2 PNIF values (in L/min) for challenges with grass pollen, birch pollen and house dust mite (HDM)
PNIF peak nasal inspiratory flow, SD standard deviation
Pollen Concentration PNIF baseline (±SD) PNIF 30 min (±SD) PNIF 60 min (±SD) PNIF 90 min (±SD) PNIF 120 min (±SD)
Grass Placebo 123.4 (±55.4) 106.8 (±40.4) 109.3 (±44.9) 114.3 (±51.1) 115.2 (±56.3)
4000 grains/m3 130.7 (±54.8) 102.7 (±50.9) 99.3 (±52.7) 95.7 (±52.5) 95.6 (±50.7)
8000 grains/m3 135.5 (±52.7) 98.0 (±50.9) 84.1 (±46.3) 82.5 (±47.6) 96.1 (±48.3)
Birch Placebo 132.5 (±63.1) 118.6 (±58.8) 116.4 (±56.9) 112.7 (±51.2) 117.5 (±56.9)
4000 grains/m3 143.6 (±37.5) 126.1 (±42.4) 118.9 (±41.7) 117.9 (±37.2) 120.2 (±44.2)
8000 grains/m3 140.8 (±43.3) 122.7 (±44.7) 115.6 (±45.6) 119.9 (±40.5) 118.9 (±39.5)
16,000 grains/m3 143.6 (±47.2) 118.6 (±47.8) 110.0 (±43.6) 108.6 (±53.5) 114.6 (±50.3)
HDM Placebo 136.9 (±46.4) 121.9 (±50.1) 106.1 (±52.0) 104.4 (±51.3) X
250 µg/m3 139.4 (±55.1) 95.2 (±38.6) 80.0 (±38.0) 81.5 (±40.2) X
Fig. 1 Reduction of PNIF during exposure with grass pollen in the  GA2LEN chamber. PNIF development during exposure with Phleum pratense. A 
hash marks a reduction compared to baseline p < 0.001, a dagger a reduction compared to baseline p < 0.01. Outliers are presented as degree sign, 
extreme outliers as asterisk. PNIF% from both actively exposed groups (4000 and 8000 grains/m3) is significantly lower (p < 0.05) than in the placebo 
group at every associated time of measurement. PNIF% is displayed as medians and boxplots
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compared to placebo [11,114.6 (10,331.8, 11,766.7)] 
(p < 0.001).  
Birch
28 subjects were challenged with 4000  grains/m3 of 
birch pollen, 33 subjects with 8000  grains/m3, 11 sub-
jects with 16,000  grains/m3 and 22 subjects with pla-
cebo. PNIF dropped from baseline during exposure 
22.8 (±SD 25.3  L/min) for 4000  grains/m3 concentra-
tion [PNIF% reduction 15.4%, 95% CI (8.8, 20.5)], 21.5 
(±SD 23.6  L/min) for 8000  grains/m3 [12.0%, 95% CI 
(9.4, 21.7)], 30.7 (±SD 21.9  L/min) for 16,000  grains/
m3 [19.6%, 95% CI (12.5, 28.4)], and 16.2 (±SD 22.6 L/
min) for placebo [8.5%, (1.3, 17.1)] (Table 2; Additional 
file 1: Table S1). Friedman test found significant differ-
ences for every actively exposed group compared to 
their baseline value in PNIF%. In detail, at challenges 
with 8000  grains/m3 each point of measurement dif-
fered significantly from the baseline, whereas at chal-
lenges with 4000 and 16,000  grains/m3 each point of 
measurement from minute 60 and further on did. In 
the placebo group, only at point of measurement at 
minute 90 a significant difference compared to base-
line could be found (Fig.  2). However, PNIF% showed 
no significant difference between the challenge groups, 
even though a trend was clearly recognizable. Hence, 
the three groups that got actively exposed to birch pol-
len were summarized into one active group. In addi-
tion, only those tests runs were included where test 
subjects reached a TNSS greater than two points on 
at least two symptom check cards. Eventually, 38 chal-
lenges were included into the active group, the placebo 
group remained the same. Mean reduction from base-
line for absolute PNIF values in the active group was 
31.2 (±SD 24.8  L/min) and 20.4%, 95% CI (15.8, 25.0) 
for relative values (Additional files 2, 3: Tables S2, S3). 
Values in the placebo group stayed the same as reported 
earlier. Mann–Whitney-U test found significant dif-
ferences when comparing the PNIF% values between 
active and placebo group after 60  min (z  =  −2.809, 
p =  0.005), after 90  min (z = −2.380, p =  0.017) and 
after 120 min (z = −2.133, p = 0.033) (Additional file 4: 
Fig. S1). Moreover, the AUC of PNIF% was significantly 
lower in the active group [9878.6 (9115.4, 10,250.0)] 
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Fig. 2 Reduction of PNIF during exposure with birch pollen in the  GA2LEN chamber. PNIF development during exposure with Betula pendula. A 
hash marks a reduction compared to baseline p < 0.001, a dagger a reduction compared to baseline p < 0.01 and a double dagger a reduction 
compared to baseline p < 0.05. Outliers are presented as degree sign, extreme outliers as asterisk. PNIF% is displayed as medians and boxplots
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than in the placebo group [11,092.9 (10,105.3, 11,921.1)] 
(z = −2.754, p = 0.006).
House dust mite
24 patients were exposed to 250  µg/m3 HDM material, 
18 patients participated in a placebo run. Mean change 
from baseline was 53.8 (±SD 33.9  L/min) in the active 
group and 26.1 (±SD 28.7  L/min) in the placebo group 
for absolute values (Table  2; Additional file  5: Fig. S2), 
40.1%, 95% CI (25.8, 44.4) and 20.7%, 95% CI (6.1, 33.3) 
for relative values, respectively (Additional file  1: Table 
S1). Mann–Whitney-U test found significant differences 
between both groups regarding their PNIF% values after 
30 min (z = −2.975, p = 0.003), after 60 min (z = −2.328, 
p  =  0.020) and after 90  min (z  =  −2.327, p  =  0.020) 
(Fig.  3). Similar to the other conducted challenges with 
grass and birch, comparisons of absolute PNIF values 
found no significant difference due to the unequal base-
lines. AUC for PNIF% was significant lower in the active 
group [6156.4 (5666.7, 7100.0)] than in the placebo group 
[7440.0 (6458.8, 8727.3)] (z  = −2.872, p =  0.004). Fur-
thermore, Friedman test showed a significant difference 
at each point of measurement during exposure compared 
to baseline in the active group. Though, the placebo 
group differed also significantly from their baseline value 
at points of measurement after 60 min and after 90 min.
Comparison between the allergens
Please find these results in the Additional file 6: Appen-
dix S1 and Additional file 7: Figure S3.
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Fig. 3 Reduction of PNIF during exposure with house dust mite (Der p 1) in the  GA2LEN chamber. PNIF development during exposure with house 
dust mite material. A hash marks a reduction compared to baseline p < 0.001, a dagger a reduction compared to baseline p < 0.01. Outliers are 
presented as degree sign. PNIF% from the actively exposed group (250 µg/m3) is significantly lower (p < 0.05) than in the placebo group at every 
associated time of measurement. PNIF% is displayed as medians and boxplots
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Correlations
Positive weak to moderate correlations could be found 
between PNIF and PEF  (rs  =  .499, p  <  0.001), PNIF 
and height  (rs =  .404, p  <  0.001) and PNIF and weight 
 (rs =  .308, p  <  0.001). A correlation between PNIF and 
age was not visible  (rs  =  .005, p  =  0.96). Furthermore, 
an inverse moderate to strong correlation could be com-
puted between PNIF% and TNSS  (rs = −.585, p < 0.001), 
as well as inverse weak to moderate correlations between 
PNIF% and nasal congestion score  (rs = −.415, p < 0.001), 
and PNIF% and VAS of overall subjective symptoms 
 (rs = −.361, p < 0.001) (Fig. 4).
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Fig. 4 Correlations between peak nasal inspiratory flow (PNIF) and oral peak expiratory flow (PEF) (a), height (b), and weight (c) with n = 86, and 
relative peak nasal inspiratory flow compared to baseline (PNIF%) and mean VAS change from baseline (d), mean Total Nasal Symptom Score (TNSS) 
(e), and mean nasal congestion score (f) with n = 203
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Discussion
PNIF has been recommended and been used as an out-
come parameter in allergen immunotherapy trials [19, 
20], pharmacological trials [21, 22], nasal allergen chal-
lenges [23, 24], before surgical interventions [25, 26], and 
is also a feasible tool in assessing nasal patency in both 
children [27] and adults [28, 29]. This was the first study 
to evaluate peak nasal inspiratory flow as an outcome 
parameter in an allergen exposure chamber. Overall, 86 
subjects participated in 203 individual challenges with 
either grass pollen, birch pollen, house dust mite material 
or placebo. At baseline, male subjects reached a PNIF of 
174.2 ± 59.9 L/min and female subjects of 126.3 ± 31.0 L/
min. Measurements were taken in a seated position, as 
there exists no significant difference to standing position 
[30], and the best of at least two successful measurements 
was noted due to no additional benefit in a third trial [15]. 
Reproducibility and no demand for priming exposures 
were previously reported [14]. Our results confirm a study 
by Denguezli Bouzgarou et  al. who found almost exact 
same values in a healthy North African population with a 
mean PNIF in male subjects of 174 ± 54 and 126 ± 33 L/
min in female subjects [31]. Looking at data for a Euro-
pean population our values were lower than data obtained 
by Åkerlund et al. [32], but comparable to findings from 
Ottaviano et  al. with a PNIF of 143  ±  48.6  L/min for 
male and 121.9 ±  36  L/min for female [33]. A study by 
Klossek et al. in a French population found clearly lower 
normal ranges in PNIF though. Even when only report-
ing the values obtained from the subjects, who reported 
no nasal discomfort at all, men had a mean PNIF of 
100.3  ±  43.6  L/min and women of 79.3  ±  32.2  L/min 
[34]. However, an explanation for these low values was 
not found. The greatest reduction in PNIF was elicited 
by HDM in our study, followed by grass pollen and birch 
pollen. PNIF also decreased mildly in the placebo group, 
even when no patient in the chamber was exposed to an 
allergen. Whether the decline results apart from the pla-
cebo effect itself, from decreasing patients’ effort during 
the exposure, increased osmolarity of nasal mucus due to 
increased ventilation from the measurements, or despite 
55% humidity too dry air, needs to be further investigated. 
Standard deviation of some results for absolute PNIF val-
ues exceeded the mean value caused by the unequal distri-
bution. Hence, it is of utmost importance to compare the 
relative reductions. Decreased PNIF is known in HDM 
allergy as allergic subjects usually present with nasal 
obstruction [35]. However, little is known about the dif-
ferences in nasal symptoms elicited by different airborne 
pollen. In our challenges PNIF decreased in subjects 
exposed to grass pollen much greater in both absolute and 
relative values than in subjects exposed to birch pollen. 
Nonetheless, both kinds of pollen had in common that 
the more the pollen concentration increased the more 
PNIF reduction was induced. These results imitate the 
conditions in nature as described by Caillaud et  al. who 
described a linear relationship between birch pollen con-
centration and symptoms elicited until symptom severity 
reaches a plateau when a certain threshold concentration 
is exceeded [36]. As demanded by a recently published 
position paper from the European Academy of Allergy 
and Clinical Immunology (EAACI) it is important to com-
pare the obtained results between the existing exposure 
chambers [37]. To the authors knowledge only two studies 
conducted in an Environmental Exposure Unit (EEU) in 
Kingston, Ontario have used PNIF as an outcome param-
eter in clinical trials [38, 39]. Both studies were clinical 
evaluations of the EEU for birch pollen and grass pollen 
exposure, respectively. Focusing just on the reported PNIF 
data for provocations with grass pollen, the mean reduc-
tion of PNIF after 180 min of exposure compared to base-
line to either 2500 or 3500 grains/m3 grass pollen (Lolium 
perenne) was 29.8 and 42.9 L/min, respectively, resulting 
in a relative reduction of 30.4 and 34.2%, respectively. 
These results match our findings with a PNIF reduction 
of 35.2  L/min (relative reduction 29.3%) after 120  min 
exposure to 4000 grains/m3 of grass pollen compared to 
baseline. However, allergic patients were not provoked to 
placebo in the EEU, thus the effect of the chamber itself to 
allergic subjects is unknown. Furthermore, the technology 
of pollen distribution is totally different in both chambers. 
Whereas in the EEU and most of the other existing cham-
bers pollen gets distributed via fans all over the exposition 
room, the  GA2LEN chamber provides an individual expo-
sure to every subject giving an exact knowledge of the 
concentration every test subject got exposed to. Hence, 
even when using the same allergen concentration the 
results might not be directly comparable. Both chambers 
provoked less reduction in PNIF during challenges with 
birch pollen. That is why it can be suspected that birch 
allergy elicit less nasal congestion and other symptoms are 
more present. This needs to be further evaluated. In our 
study, we found moderate positive correlations between 
PNIF and weight, height and oral peak inspiratory flow. 
Even though some publications denied a correlation 
between PNIF and weight [32] or PNIF and height [40], 
other studies confirmed these associations, especially for 
PNIF and PEF [41–43]. In our study PNIF and subjec-
tive nasal symptoms were found to correlate inversely 
with a Spearman’s rank correlation coefficient  rs = −0.59 
between PNIF and TNSS, and  rs = −0.42 between PNIF 
and nasal congestion score. Other studies, that were using 
exactly the same TNSS as we did, computed correlations 
from −0.50 to −0.62 between PNIF and TNSS, confirm-
ing our analysis and thus consolidate the usefulness of 
PNIF as an objective control parameter for subjective 
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symptoms [44, 45]. Furthermore, the publication from 
Ellis et  al. reported a weak to moderate negative corre-
lation from −0.32 to −0.37 between PNIF and subjec-
tive scoring of nasal congestion, which can be validated 
and even enhanced with data obtained in the  GA2LEN 
chamber [38]. The correlation between PNIF and VAS of 
overall subjective symptoms was found to be at −0.36 in 
the  GA2LEN chamber, thus being in the range of already 
published correlations of −0.39 to −0.48 between PNIF 
and VAS [17, 28, 29]. However, these studies focused only 
on the VAS of nasal obstruction in particular. Hence, our 
findings provide additional information about the relation 
of PNIF and the actual patient’s perception of their overall 
symptom severity, which possibly represents real-life con-
ditions more accurately.
Conclusions
In conclusion, due to its portability, simple application 
and good correlation to subjective symptoms, PNIF is a 
valuable tool for provocation trials in AECs. However, 
more clinical trials comparing this outcome in different 
AECs facilities would be advisable.
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